Develops therapies targeting the immune checkpoint pathways for cancer treatment.
Tempest Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative small molecule therapeutics aimed at combating cancer. Central to its mission are two prominent clinical programs: TPST-1495, a dual antagonist targeting EP2 and EP4 receptors of prostaglandin E2, currently undergoing Phase 1 trials for various solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, also in Phase 1 trials for solid tumors. Additionally, the company is advancing TREX-1, a pivotal cellular enzyme crucial for regulating the innate immune response within tumors.
Founded in 2011 and headquartered in South San Francisco, California, Tempest Therapeutics emerged as an independent entity from its origins as a subsidiary of Inception Sciences, Inc. The company's robust pipeline underscores its commitment to pioneering therapeutic approaches that target critical pathways involved in cancer progression. Through strategic research and clinical development efforts, Tempest Therapeutics aims to bring transformative treatments to patients grappling with challenging oncological conditions.
With a focus on advancing precision medicine solutions, Tempest Therapeutics leverages its scientific expertise and collaborative partnerships to drive innovation in cancer therapy. By harnessing cutting-edge technologies and insights into tumor biology, the company seeks to redefine standards of care and improve outcomes for cancer patients worldwide.